Interferon alphacon-1 Active Protein | IFN-a con active protein

Human Interferon alphacon-1 Recombinant

Cat. Num. AAA553232

• Purity: >97%, as determined by SDS-PAGE and HPLC
• Synonyms: Interferon alphacon-1; Human Interferon alphacon-1 Recombinant; Human Interferon alphacon 1 Recombinant; ifna; interferon alpha; ifn-a; IFN-a con active protein

• Host: E. coli
• Purity/Purification: >97%, as determined by SDS-PAGE and HPLC
• Form/Format: Recombinant Interferon alpha 2a was lyophilized from a 0.2 um filtered PBS solution pH 7.0.

• Host Note: Optimized DNA sequence encoding Human Interferon-alpha concensus mature chain was expressed in Escherichia Coli.
• Molecular Weight Note: Recombinant Interferon alpha concensus is a disulfide-linked monomeric protein consisting of 166 amino acid residue subunits, and migrates as an approximately 19 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE.
• Biological Activity: The activity was determined by a viral resistance assay of Human WISH cells, and was found to be in the range of 1x10⁸ IU/mg.
• Endotoxin: Endotoxin content was assayed using a LAL gel clot method.; Endotoxin level was found to be less than 0.1 ng/ug (1EU/ug).
• Reconstitution: A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
• Preparation and Storage: The lyophilized protein is stable for at least 2 years from date of receipt at -20°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2°-8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

Product Categories/Family for IFN-a con active protein

Cytokines

References

• cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-: association of pretreatment serum levels with survival .Ann. Onc., Oct 2009; 20: 1682 - 1687.
• sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy .Clinical Trials, Sep 2009; 10.1177/1740774509344633.
• role of schlafen 2 (slfn2) in the generation of interferon -induced growth inhibitory responses .J. Biol. Chem., Sep 2009; 284: 25051 - 25064.
• palmitoylation of interferon- (ifn-) receptor subunit ifnar1 is required for the activation of stat1 and stat2 by ifn- .J. Biol. Chem., Sep 2009; 284: 24328 - 24340.
• lack of association between the interferon- signature and longitudinal changes in disease activity in systemic lupus erythematosus .Ann Rheum Dis, Sep 2009; 68: 1440 - 1446.